Trial ID or NCT#

NCT00226655

Status

NOT RECRUITING

Purpose

The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.

Official Title

An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Lawrence Recht, MD
Neuro-oncologist
Professor of Neurology and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Laurence Katznelson, MD
Neuroendocrinologist
Professor of Neurosurgery and of Medicine (Endocrinology) at the Stanford University Medical Center, Lucile Salter Packard Children's Hospital and at the Palo Alto Veterans Affairs Health Care System
Paul Graham Fisher, MD
Neuro-oncologist, Pediatric neurologist
Bing Director of the Program in Human Biology, Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Health Research and Policy (Epidemiology) at SUMC

Contact us to find out if this trial is right for you.

CONTACT

Lynn Adler
(650) 725-8630